Diabetes Mellitus

Diabetic Nephropathies

Fenofibrate 100 mg or 300 mg (according to CrCl)

Fenofibrate

Singapore General Hospital

Effects of Fenofibrate Therapy in Diabetic Nephropathy

Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy

Percentage change in serum concentration of palmitoylcarnitine following 30 days of fenofibrate treatment compared to baseline

Percentage change in serum concentration of acetylcarnitine following 30 days of fenofibrate treatment compared to baseline

Percentage change in serum concentration of leucine following 30 days of fenofibrate treatment compared with baseline

Percentage change in serum concentration of isoleucine following 30 days of fenofibrate treatment compared with baseline

Percentage change in serum concentration of valine following 30 days of fenofibrate treatment compared with baseline

Absolute change in serum triglyceride (mmol/L) concentration following 30 days of fenofibrate treatment with baseline

Change in rate of fat oxidation (g/min) following 30 days of fenofibrate treatment

Change in ETDRS scale following 30 days of fenofibrate treatment

National Medical Research Council (NMRC), Singapore

In this single-centre, open label study, 300 adults with DN will be recruited over 3 years. Following screening and baseline metabolic evaluations, eligible subjects will be treated with fenofibrate for 30-days and re-assessed.

patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice

patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime

Cardiopulmonary Bypass

Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients

Plasmalyte A

Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients

Ringer Lactate

Comparative Analysis Between Ringer's Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime

Comparative Analysis Between Ringer's Lactate vs Acetate Containing Balanced Crystalloid Solution (Plasma Lyte-A) as Cardiopulmonary Bypass Prime

Arterial blood gas analysis at before induction, five minutes after CPB, at the end of the termination of CPB, half an hour stay in the ICU soon after the patient is shifted from completion of surgery, before the patient is extubated

Doniparthi Pradeep

Junior Resident, Department of General Surgery

Postgraduate Institute of Medical Education and Research

treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.

treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)

Bladder Cancer

Urinary Diversion

to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias

restrictive intraoperative fluid substitution

A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure

assessment of the pelvic venous pressure

Dep. of Anesthesiology and Pain Therapy, Bern University Hospital

Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy

Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Blood Loss and Perioperative Outcome in Patients Undergoing Open Radical Cystectomy

Dr Patrick Wüthrich/Department of Anesthesiology and Pain Therapy

University Hospital Inselspital, Berne

placebo 3cps/days 4 weeks over 6 during 1 year

sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year

Liver Cancer

sunitinib malate

Placebo

transarterial chemoembolization

Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part

CHU Nord

Institut Sainte Catherine

CHU J Minjoz

Institut Bergonié

CHU Côte de Nacre

Clinique des Cèdres

CHU Bocage

Hôpital Claude Huriez

Hopital Dupuytren

CHBS

Hôpital Privé Jean Mermoz

CH Ambroise Paré

CH Conception

CHU La Timone

Hôpital Saint Joseph

CHRU Saint Eloi

CHU -Hôpital de l'Archet II

Hopital Tenon

Groupe Hospitalier Paris St Joseph

Hôpital Européen Georges Pompidou

CHU Jean Bernard

CHU Robert Debré

Institut Gustave Roussy

Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)

malate/blutung

Effects of Fenofibrate Therapy in Diabetic Nephropathy

Comparative Analysis Between Ringer's Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime

Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy

Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird